Abiopharma

New Form 144 - VEEVA SYSTEMS INC Filed: 2025-07-03 AccNo: 0001950047-25-004834 Size: 4 KB

New Form 8-K - Neuraxis, INC Filed: 2025-07-03 AccNo: 0001641172-25-017723 Size: 440 KB Item 1.01: Entry into a Material Definitive Agreement Item 1.02: Termination of a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item …

New Form 4 - Liquidia Corp Filed: 2025-07-03 AccNo: 0001104659-25-065705 Size: 5 KB

New Form 4 - Liquidia Corp Filed: 2025-07-03 AccNo: 0001104659-25-065704 Size: 5 KB

New Form 3 - Liquidia Corp Filed: 2025-07-03 AccNo: 0001104659-25-065702 Size: 7 KB

New Form 6-K - Clearmind Medicine Inc. Filed: 2025-07-03 AccNo: 0001213900-25-061359 Size: 32 KB

New Form 3 - Liquidia Corp Filed: 2025-07-03 AccNo: 0001104659-25-065701 Size: 10 KB

New Form 144 - Mirum Pharmaceuticals, Inc. Filed: 2025-07-03 AccNo: 0001950047-25-004832 Size: 5 KB

New Form 4 - Bespoke Extracts, Inc. Filed: 2025-07-03 AccNo: 0001213900-25-061353 Size: 4 KB

New Form 8-K - AbbVie Inc. Filed: 2025-07-03 AccNo: 0001551152-25-000034 Size: 263 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 144 - Viking Therapeutics, Inc. Filed: 2025-07-03 AccNo: 0001950047-25-004829 Size: 4 KB

New Form 4 - VOLITIONRX LTD Filed: 2025-07-03 AccNo: 0001477932-25-004916 Size: 6 KB

New Form 4 - VOLITIONRX LTD Filed: 2025-07-03 AccNo: 0001477932-25-004917 Size: 5 KB

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)